Urology Times staff

“The hope is that the research and technology will be mature enough at the time that they're ready to use that tissue for a biological child,” says Amanda J. Saraf, DO.

"What we think is really nice about it is it's not required to have it into an electronic medical record for this to work on the wards," says Jennifer Ann Meddings, MD.

“It will be interesting to see how this plays out long-term in the changing political scheme, as well as the general trend of the current generation potentially having different thoughts in terms of wanting to have children or not in the future,” says Catherine S. Nam, MD.

“We believe this is going to be the next rendition of how we can train physicians, as well as make surgeons more effective at their job,” says Nitin K. Yerram, MD.

"If we want to do a targeted therapy, we have to know exactly where and what we are treating," says Gamal M. Ghoniem, MD, FACS, ABU/FPMRS.

"By helping them see what could be going on with their health and knowing when to reach out for help, we think that's a fantastic way to begin to change the paradigm when it comes to men and prostate cancer in the US," says Motolani Adedipe, PhD, DPh, MSc.

"The cases that I've done have been here, at least, have been some of the most, I guess, impactful and really make me proud and happy to be a urologist and to do something [for which] the patients are incredibly grateful," says John Michael DiBianco, MD.

"We did see a rise in 2020, and that's been kind of maintained in 2021 and 2022, but overall, it looked like a pretty low rate," says Brian R. Lane, MD, PhD, FACS.

"My goal in the trip was not to see how many patients I could operate on, how many doctors I could train, [it was] to help 1 person train," says Joel Gelman, MD.

“We get exposure and get an opportunity to work with experts in the field before we even start fellowship, so that we can develop a baseline of expertise in areas of Peyronie's disease, erectile dysfunction, infertility, and managing sexual medicine and fertility in men across the board,” says Jacob Rust, MD.

"If we don't take the time to speak to trainees, an already vulnerable population, we're missing an opportunity to help them early," says Andrew M. Harris, MD.

"A surprise finding was the increase in opioid fulfillment beyond the 7-day postoperative period, which was really unexpected," says Laura Gressler, MS, PhD.

"I think it really is going to change my practice," says Akhil Das, MD, FACS.

“Fortunately, the chemotherapy regimens that Dr. Einhorn put together in combination with the surgical approaches with Dr. Donohue really revolutionized the cure rates and the care for men with testicular cancer,” says Clint Cary, MD, MPH, MBA.

"The scale of that linkage and the manner with which we were able to do it is really exciting and opens the door for a lot of future discovery," says Michael S. Leapman, MD, MHS.

“It's been exciting to be on the forefront of new technology and new implants to help men regain their sexual function and empower them,” says Dr. Helen L. Bernie, DO, MPH.

"When it came down to linking the clinical information with both biopsy reports as well as the prostatectomy pathology reports, we didn't have much of a challenge with that," says Randy A. Vince Jr, MD, MS.

"Unless there's an anatomic reason why you can't use a bladder scanner reliably, then, really you should be using a bladder scanner," says Jennifer Ann Meddings, MD, MSc.

"Access to clean water and having reliable sewage systems is a huge public health issue," says Elisabeth M. Sebesta, MD.

“We will do exactly what we have done in terms of prototype of our processes, our tools, our design, and how we follow these patients up, and expand this from 10,000 men in less than 2 years to 1 million men in next 10 years,” says Ashutosh K. Tewari, MD.

"You definitely need to be very adaptable. You have to have a great team," says John Michael DiBianco, MD.

"I'm very transparent with my patients by telling them these exist. I don't provide them because we don't have enough level of evidence or body of research supporting them," says Ramy Abou Ghayda, MD, MPH, MBA.

"We wanted to look at the importance of genetic testing in patients with GU cancer and the impact that it has on their treatment decision-making, and the pathways that we put them on," says Mouneeb Choudry, MD.

"My goal as a 'plumber'/urologist is to see if we can find better options and also understand the mechanism behind the disease," says Zhina Sadeghi, MD.

"One of the main conclusions that we can take from our study is that although the current classification systems are somewhat accurate, they are far from being perfect," says Félix Guerrero-Ramos, MD, PhD, FEBU.

"We can individualize the access and the way we do the operation based on the patient's characteristics, and that hasn't happened in a very long time," says Ketan K. Badani, MD.

“This is a great opportunity for public outreach and re-education on the common misconceptions surrounding vasectomy,” says Catherine S. Nam, MD.

"For [men] to come to the practice and talk about [a sensitive issue] is a big step," says Adity Dutta, MSN, AGACNP-BC.

"What we found is that across the board, all 16 scores did relatively well with the association between an elevated polygenic risk score and prostate cancer incidence," says Randy A. Vince Jr, MD, MS.

“One thing is we’re trying to create an atmosphere in the center whereby men feel at ease, they're comfortable talking to their provider who is specialized in this field,” says Ramy Abou Ghayda, MD, MPH, MBA.